Jörg Neermann

Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform can address a wide range of autoimmune and immunologic diseases. Imotopes™ are modified synthetic peptides, which specifically block improper immune activity. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no effective therapeutic alternative and has the potential to cure patients without impairing their immune defenses. Our vision is to become a leader in the field of active specific immunotherapy and to prevent, stop and potentially cure autoimmune diseases. Headquartered in Liège, Belgium, Imcyse was founded as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s Imotope™ technology platform is protected by a robust, international intellectual property portfolio. Our lead Imotope™, IMCY-0098, is in phase 2 clinical testing for early onset type 1 diabetes.

Immunic (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Privacy Policy: https://imux.com/privacy-policy/

ViCentra BV, Medical Devices, Utrecht Founded in 2013 in Utrecht, The Netherlands, ViCentra is a leading early stage commercial company focused on the development, manufacturing and commercialisation of the Kaleido insulin pump designed to help people with diabetes live life on their own terms. Driven by our belief in the power of innovative healthcare products that put the people first and a desire to be meaningfully different, Kaleido aims to reduce the impact that diabetes can have on daily life.

Spine-related pain is taking a huge toll on our society: more bed-days, more days off work, and at a greater financial cost to westernized healthcare than any other condition. We’re on a mission to ease this burden through superior biologics for better spinal fusions. We believe that a greater quality and quantity of science holds the key to easing the burden of back surgery. Every day, we put our 150 years’ combined research experience to work in achieving this, which includes: 10 well-controlled Level I-III clinical trials initiated. >25 orthobiologics-related patents. >400 patients evaluated in Level I, randomized controlled clinical trials. >15,000 patients successfully treated. Today, nearly 1 in 5 spinal fusions fail. But what can we do to change this situation - for the benefit of patients, surgeons and our wider society? This is the question that drives us at Kuros. Every day our team works across three continents to unlock the hidden secrets of bone healing through our research, development & technology program: Project Fusion. To deliver the ideal bone graft, we believe you need the highest quality & quantity of scientific evidence behind it. Which is why Project Fusion brings together an unprecedented blend of scientific, pre-clinical and clinical studies – all aimed at making the unpredictable…predictable. CONTACT KUROS TO FIND OUT MORE >>>>

Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective syndromic testing products for the diagnosis of severe infectious diseases. The diagnostic solution Unyvero of Curetis enables rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques. The Unyvero diagnostic platform can be used for the diagnosis of hospitalized patients with several applications with the broadest panels to detect pathogens as the HPN (Hospitalized Pneumonia), BCU (Blood Culture Infection), ITI (Implant & Tissue Infections), IAI (Intra-Abdominal Infections) and UTI (Urinary Tract Infections). The company is based in Holzgerlingen near Stuttgart, Germany and all the products are fully developped and produced in Germany. Curetis has entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia. In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximizing the R&D and related scientific and business opportunities of the GEAR assets acquired in 2016 for the entire Curetis Group. Imprint: http://www.curetis.com/en/impress.html

Affimed N.V. (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform predictably generates customized innate cell engagers (ICE®), bispecific antibodies, which target innate immune cells to destroy tumor cells. The broad pipeline enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. It comprises wholly owned and partnered programs and builds on monotherapy or combination approaches with Natural Killer (NK) cell products or other I-O therapeutics. The lead candidate AFM13 is in development for patients with CD30+ lymphomas and has broad clinical development potential as monotherapy and in combination with NK cells and other I-O therapies, such as PD-1 inhibitors. AFM24 is specific for EGFR and CD16A and targets solid tumors. Three Phase 1 studies, with AFM24 as monotherapy or in combination with NK cells or anti-PD-L1 are ongoing. AFM28 targets CD123 and CD16A and is in development for patients relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) as mono- or combination therapy.

Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 30 FTEs as of 1 January 2022 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A3E5C40). About resminostat Resminostat is an orally administered class I, IIb and IV histone deacetylase (HDAC) inhibitor that potentially offers an approach to treating different kinds of cancer. Resminostat demonstrated that it is well tolerated and can inhibit tumor growth and proliferation, cause tumor regression, and strengthen the body’s immune response to cancer. Resminostat is currently being investigated in a pivotal study in cutaneous T-cell lymphoma (CTCL) as maintenance treatment by 4SC in Europe and by Yakult Honsha in Japan. About cutaneous T-cell lymphoma (CTCL) CTCL is a rare disease with approximately 5,000 patients being newly diagnosed in Europe each year. The disease arises from malignant transformation of T-cells, a specialized subgroup of immune cells, primarily affects the skin, but may ultimately involve lymph nodes, blood and visceral organs. Currently, CTCL is not curable and treatment options for advanced-stage CTCL are limited. Although patients respond to the available treatment options, the duration of response is often short-lived and declines as the severity of the disease increases. The key therapeutic challenge in advanced-stage CTCL is therefore to make remissions more durable by halting disease progression and improving patient’s quality of life. About the RESMAIN study – resminostat for maintenance treatment of CTCL The pivotal RESMAIN study is being conducted at more than 50 clinical centers in 11 European countries and Japan. It will include more than 190 patients who suffer from advanced-stage cutaneous T-cell lymphoma (CTCL) that have achieved disease control with systemic therapy.

Vorwerk Ventures is an independent € 150m Venture Capital Fund with € 400m under management. We define ourselves through a strong commitment towards startups that drive positive impact for the people and the planet. We lead seed rounds within our clearly defined focus areas: Consumer, Food, Health, and Climate. Our unique experience in addition to an outstanding track record provides added value for forward-thinking tech entrepreneurs. Headquartered in Berlin Germany, we are constantly on the look-out for promising opportunities starting with Seed/Series A investments of €1m to €5m and ensuring continuous support by reserving up to €15m for upcoming financing rounds. An outstanding founding team, a unique product or service addressing a substantial market framed by a strong business model are key requirements to us when it comes to making an investment decision.

Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform can address a wide range of autoimmune and immunologic diseases. Imotopes™ are modified synthetic peptides, which specifically block improper immune activity. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no effective therapeutic alternative and has the potential to cure patients without impairing their immune defenses. Our vision is to become a leader in the field of active specific immunotherapy and to prevent, stop and potentially cure autoimmune diseases. Headquartered in Liège, Belgium, Imcyse was founded as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s Imotope™ technology platform is protected by a robust, international intellectual property portfolio. Our lead Imotope™, IMCY-0098, is in phase 2 clinical testing for early onset type 1 diabetes.

Immunic (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Privacy Policy: https://imux.com/privacy-policy/

ViCentra BV, Medical Devices, Utrecht Founded in 2013 in Utrecht, The Netherlands, ViCentra is a leading early stage commercial company focused on the development, manufacturing and commercialisation of the Kaleido insulin pump designed to help people with diabetes live life on their own terms. Driven by our belief in the power of innovative healthcare products that put the people first and a desire to be meaningfully different, Kaleido aims to reduce the impact that diabetes can have on daily life.

Spine-related pain is taking a huge toll on our society: more bed-days, more days off work, and at a greater financial cost to westernized healthcare than any other condition. We’re on a mission to ease this burden through superior biologics for better spinal fusions. We believe that a greater quality and quantity of science holds the key to easing the burden of back surgery. Every day, we put our 150 years’ combined research experience to work in achieving this, which includes: 10 well-controlled Level I-III clinical trials initiated. >25 orthobiologics-related patents. >400 patients evaluated in Level I, randomized controlled clinical trials. >15,000 patients successfully treated. Today, nearly 1 in 5 spinal fusions fail. But what can we do to change this situation - for the benefit of patients, surgeons and our wider society? This is the question that drives us at Kuros. Every day our team works across three continents to unlock the hidden secrets of bone healing through our research, development & technology program: Project Fusion. To deliver the ideal bone graft, we believe you need the highest quality & quantity of scientific evidence behind it. Which is why Project Fusion brings together an unprecedented blend of scientific, pre-clinical and clinical studies – all aimed at making the unpredictable…predictable. CONTACT KUROS TO FIND OUT MORE >>>>